- Home
- SAFE vs RCUS Comparison
SAFE vs RCUS Comparison
Compare SAFE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- RCUS
- Stock Information
- Founded
- SAFE 2016
- RCUS 2015
- Country
- SAFE United States
- RCUS United States
- Employees
- SAFE N/A
- RCUS N/A
- Industry
- SAFE Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SAFE Real Estate
- RCUS Health Care
- Exchange
- SAFE Nasdaq
- RCUS Nasdaq
- Market Cap
- SAFE 1.1B
- RCUS 906.4M
- IPO Year
- SAFE 2017
- RCUS 2018
- Fundamental
- Price
- SAFE $15.34
- RCUS $9.98
- Analyst Decision
- SAFE Buy
- RCUS Buy
- Analyst Count
- SAFE 8
- RCUS 10
- Target Price
- SAFE $23.13
- RCUS $23.75
- AVG Volume (30 Days)
- SAFE 326.7K
- RCUS 1.2M
- Earning Date
- SAFE 07-28-2025
- RCUS 05-06-2025
- Dividend Yield
- SAFE 4.56%
- RCUS N/A
- EPS Growth
- SAFE N/A
- RCUS N/A
- EPS
- SAFE 1.46
- RCUS N/A
- Revenue
- SAFE $391,206,000.00
- RCUS $141,000,000.00
- Revenue This Year
- SAFE $0.20
- RCUS N/A
- Revenue Next Year
- SAFE $4.76
- RCUS $27.28
- P/E Ratio
- SAFE $10.44
- RCUS N/A
- Revenue Growth
- SAFE 2.64
- RCUS N/A
- 52 Week Low
- SAFE $13.68
- RCUS $6.50
- 52 Week High
- SAFE $28.80
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- SAFE 50.25
- RCUS 62.57
- Support Level
- SAFE $14.73
- RCUS $9.29
- Resistance Level
- SAFE $15.36
- RCUS $10.68
- Average True Range (ATR)
- SAFE 0.38
- RCUS 0.61
- MACD
- SAFE 0.07
- RCUS 0.10
- Stochastic Oscillator
- SAFE 74.47
- RCUS 69.57
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.